Real-time · AI · Cross-signal
Duality Biologics just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Duality Biologics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Expansion of Collaboration between Duality Biologics and Adcendo ApS for ADC Pipeline Enhancement
Nov 26, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyTherapeuticsBiopharma
Description
Duality Biologics announced the expansion of its ongoing collaboration with Adcendo ApS, focusing on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. Adcendo exercised its option to utilize Duality’s technology platform to be used in additional assets, further strengthening its ADC pipeline.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months